Coverage Overview

Texas has some of the most restrictive GLP-1 medication access in the country for obesity treatment. The state did not expand Medicaid under the ACA, leaving approximately 1.4 million Texans in the coverage gap — too much income for Medicaid but too little for marketplace subsidies. For patients seeking GLP-1s specifically for weight management, the pathways require more effort than in coverage-friendly states like California or New York. That said, Texas residents have several viable options through commercial insurance, manufacturer programs, and telehealth providers.

Texas Medicaid

Texas Medicaid covers GLP-1 medications for Type 2 diabetes management through its managed care plans, including Molina Healthcare, UnitedHealthcare Community Plan, Amerigroup, and Superior HealthPlan. However, Texas Medicaid does not currently cover anti-obesity medications for weight management alone — GLP-1 coverage requires a diabetes diagnosis.

Medicaid eligibility in Texas is extremely narrow: Only pregnant women, children, parents with very low income (approximately 15% of the Federal Poverty Level, or ~$3,600/year for a family of three), and individuals with disabilities qualify. Texas has the highest uninsured rate in the nation at approximately 17% of the population.

For Medicaid-enrolled patients with Type 2 diabetes:

Prior authorization is required for all GLP-1 medications
Step therapy may require trying metformin and/or a sulfonylurea before GLP-1 approval
Preferred agents vary by managed care plan — check your specific plan’s formulary
Documentation of A1C levels and current diabetes management is required

Commercial Insurance in Texas

Coverage for GLP-1 medications through Texas employer plans varies dramatically:

Blue Cross Blue Shield of Texas — covers GLP-1s for diabetes; obesity coverage depends on employer plan selection. Large employer groups increasingly include anti-obesity medications.
Aetna (TX) — covers semaglutide and tirzepatide for diabetes. Weight management coverage requires specific plan riders that not all employers purchase.
UnitedHealthcare (TX) — coverage varies by employer. Some UHC plans in Texas cover Wegovy and Zepbound for obesity with prior authorization; others exclude weight-loss drugs entirely.
Cigna (TX) — similar pattern: diabetes coverage is standard, obesity coverage is plan-dependent.

Prior authorization is almost universally required in Texas for GLP-1 prescriptions regardless of indication. Expect to provide BMI documentation, comorbidity records, and evidence of lifestyle modification attempts.

Medicare in Texas

Medicare rules are federal, so Texas Medicare Part D beneficiaries follow the same coverage pathways as all other states. GLP-1s for Type 2 diabetes (Ozempic, Mounjaro, Trulicity) are covered under Part D formularies with standard prior authorization. For weight management, the Medicare GLP-1 Bridge Program launching July 2026 will cover Wegovy and Zepbound for beneficiaries with obesity and cardiovascular disease — this applies to Texas Medicare enrollees automatically.

Eligibility Requirements

Prior authorization is required by virtually all Texas insurers
Type 2 diabetes diagnoses have the strongest approval pathway and highest success rate
Obesity-only coverage is narrower and typically requires documented BMI ≥30 (or ≥27 with comorbidities), plus 3–6 months of lifestyle modification documentation
Supporting documentation from your physician significantly improves approval odds
For Medicaid: diabetes diagnosis is effectively required for GLP-1 access

Appeals Process

If your Texas insurer denies GLP-1 coverage:

Internal appeal: File within 180 days of denial. Texas law requires insurers to respond within 30 days for standard appeals, 72 hours for urgent cases.
External review: If the internal appeal fails, request an independent review through the Texas Department of Insurance (TDI). File online at tdi.texas.gov or call 1-800-252-3439.
Documentation tips: Include your physician’s letter of medical necessity, BMI trends over 6+ months, comorbidity records, documentation of prior diet/exercise/behavioral interventions, and clinical trial evidence supporting GLP-1 efficacy for your specific condition.

Appeals overturn approximately 40–50% of initial GLP-1 denials in Texas — it’s worth pursuing if your clinical case is strong.

Cash-Pay and Telehealth Options

For uninsured or coverage-denied Texas patients, manufacturer programs and telehealth are the primary pathways:

NovoCare: Injectable Wegovy at $349/month, Wegovy Pill at $149/month, Ozempic at $349/month — no insurance required
LillyDirect: Zepbound at $299–449/month depending on dose — direct from Eli Lilly
Telehealth providers: Hims, Ro, Found, and others operate in Texas with compounded and branded options starting at $149/month

Texas allows telehealth prescribing for GLP-1 medications through video consultations, making these programs accessible statewide including rural areas.

Texas GLP-1 Coverage Guide

Medicaid Status

Medicare Eligibility